MedTrace Logo

Creatine Supplementation During GLP-1a Therapy

NCT07625202 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-06-04

No results posted yet for this study

Summary

GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.

Conditions

Interventions

DIETARY_SUPPLEMENT

Dietary supplementation during a 12 week resistance-training program (placebo)

Placebo

DIETARY_SUPPLEMENT

Dietary supplementation during a 12 week resistance-training program (creatine)

creatine supplementation

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Philip Chilibeck, PhD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-25
Primary Completion
2027-05-30
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07625202 on ClinicalTrials.gov